The Japanese regulatory authorities have approved the drug cocktail of casirivimab and imdevimab from Roche and Regeneron for the treatment of patients with mild to moderate Covid-19 symptoms. Japan is the first country to approve the mix with the brand name Ronapreve, Roche said in a media release on Tuesday.
Ronapreve is a mixture of the two mentioned artificial antibodies that create resistance to the virus. The drug was developed by the US biotechnology company Regeneron Pharmaceuticals in partnership with Roche.
Although the drug has not yet been approved in Switzerland, the federal government had already ordered 3,000 doses in April. Although the concentrate has not yet been approved, Swissmedic approved the prescription as an exception. The USA had already granted emergency approval for the drug in November 2020. In the EU, too, the drug is already being used without authorization. (SDA)
Published: 07/20/2021, 7:40 a.m.
Last updated: July 20, 2021, 25 minutes ago